Explore /
Poster
/ A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).

A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).

Authors

Choong-kun Lee

Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Choong-kun Lee , Jaekyung Cheon , Hong Jae Chon , Min Hwan Kim , Jin Won Kim , Myung Ah Lee , Hyung Soon Park , Myoung Joo Kang , Joung-Soon Jang , Hye Jin Choi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT04722133

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS4161)

DOI

10.1200/JCO.2021.39.15_suppl.TPS4161

Abstract #

TPS4161

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

$Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).$